Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma
- PMID: 31725923
- DOI: 10.1002/ajh.25682
Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma
References
REFERENCES
-
- Bentley S. WHO classification of tumours: pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Clin Lab Haematol. 2003;25(3):201-201. https://doi.org/10.1046/j.1365-2257.2003.00518.x.
-
- NCCN. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphoma. 2018. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
-
- Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804-809. https://doi.org/10.1002/ajh.21250.
-
- Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11(2):185-189. https://doi.org/10.1016/J.CLML.2011.03.008.
-
- Castillo JJ, Guerrero-Garcia T, Baldini F, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-682. https://doi.org/10.1111/bjh.15156.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources